These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 18056843

  • 1. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.
    Konig H, Holyoake TL, Bhatia R.
    Blood; 2008 Feb 15; 111(4):2329-38. PubMed ID: 18056843
    [Abstract] [Full Text] [Related]

  • 2. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
    Konig H, Copland M, Chu S, Jove R, Holyoake TL, Bhatia R.
    Cancer Res; 2008 Dec 01; 68(23):9624-33. PubMed ID: 19047139
    [Abstract] [Full Text] [Related]

  • 3. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
    Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, Frost P, Ye F, Boschelli DH, Boschelli F.
    Cancer Res; 2003 Jan 15; 63(2):375-81. PubMed ID: 12543790
    [Abstract] [Full Text] [Related]

  • 4. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors.
    Konig H, Holtz M, Modi H, Manley P, Holyoake TL, Forman SJ, Bhatia R.
    Leukemia; 2008 Apr 15; 22(4):748-55. PubMed ID: 18273048
    [Abstract] [Full Text] [Related]

  • 5. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
    Chu S, Holtz M, Gupta M, Bhatia R.
    Blood; 2004 Apr 15; 103(8):3167-74. PubMed ID: 15070699
    [Abstract] [Full Text] [Related]

  • 6. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
    Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, Arber DA, Slovak ML, Forman SJ.
    Blood; 2003 Jun 15; 101(12):4701-7. PubMed ID: 12576334
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
    Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL.
    Blood; 2005 May 15; 105(10):3995-4003. PubMed ID: 15657179
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
    Lin H, Chen M, Rothe K, Lorenzi MV, Woolfson A, Jiang X.
    Oncotarget; 2014 Sep 30; 5(18):8637-50. PubMed ID: 25226617
    [Abstract] [Full Text] [Related]

  • 17. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.
    Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza R, Magistroni V, Andreoni F, Scapozza L, Formelli F, Gambacorti-Passerini C.
    Cancer Res; 2006 Dec 01; 66(23):11314-22. PubMed ID: 17114238
    [Abstract] [Full Text] [Related]

  • 18. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
    Jabbour E, Cortes J, O'Brien S, Giles F, Kantarjian H.
    Semin Hematol; 2007 Jan 01; 44(1 Suppl 1):S25-31. PubMed ID: 17292738
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.
    Corbin AS, O'Hare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW, Cortes JE, Druker BJ, Deininger MW.
    Cancer Res; 2013 Sep 15; 73(18):5775-86. PubMed ID: 23887971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.